---
title: PENG Block vs. ESP Block for Pediatric Hip Surgery
nct_id: NCT06087549
overall_status: COMPLETED
phase: PHASE4
sponsor: Poznan University of Medical Sciences
study_type: INTERVENTIONAL
primary_condition: Hip Dysplasia
countries: Poland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06087549.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06087549"
ct_last_update_post_date: 2024-02-28
last_seen_at: "2026-05-12T07:30:34.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# PENG Block vs. ESP Block for Pediatric Hip Surgery

**Official Title:** PENG Block vs. ESP Block for Pediatric Hip Surgery. A Randomized, Prospective Double-blinded Clinical Trial.

**NCT ID:** [NCT06087549](https://clinicaltrials.gov/study/NCT06087549)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Poznan University of Medical Sciences
- **Conditions:** Hip Dysplasia, Hip Injuries, Hip Fractures, Hip Disease
- **Start Date:** 2023-10-17
- **Completion Date:** 2024-02-23
- **CT.gov Last Update:** 2024-02-28

## Brief Summary

The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries.

## Detailed Description

The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries. In addition, we aim to determine the optimal volume of local anesthetics needed to achieve a satisfactory level of analgesia.

## Eligibility

- **Minimum age:** 2 Months
- **Maximum age:** 12 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

\- pediatric patients aged between 0-12 years who will undergo hip surgery

Exclusion Criteria:

* a history of chronic pain use of gabapentin/pregabalin for \> 3 months opioid use \> 1 repeated opioid prescription in the last three months
* morbid obesity (BMI \> 99th percentile)
* Infection at block application area
* coagulopathy
```

## Arms

- **Control group** (ACTIVE_COMPARATOR) — regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine
- **Pericapsular nerve group block (PENG) group** (ACTIVE_COMPARATOR) — regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + PENG block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
- **Erector Spinae Plane Block (ESPB) group** (ACTIVE_COMPARATOR) — regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + ESP block - 0.5mL/kg 0.2% ropivacaine, max. 20mL

## Interventions

- **Pericapsular nerve group block using 0.2% ropivacaine** (DRUG) — Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
- **Erector Spinae Plane Block using 0.2% ropivacaine** (DRUG) — Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
- **Standard care** (OTHER) — No erector spinae block and no pericapsular nerve group block

## Primary Outcomes

- **FLACC score** _(time frame: 48 hours after surgery)_ — The FLACC scale or Face, Legs, Activity, Cry, Controllability Scale is used to assess pain for children between the ages of 2 months and seven years or individuals unable to communicate their pain. The scale is scored in a range of 0-10, with 0 representing no pain.

## Secondary Outcomes

- **NLR** _(time frame: 48 hours after surgery)_
- **PLR** _(time frame: 48 hours after surgery)_
- **total opioid consumption** _(time frame: 48 hours after surgery)_

## Locations (1)

- Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland, Poznan, Wielkopolska, Poland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of spine diseases and pediatric orthopedics, university of medical sciences, poznań, poland|poznan|wielkopolska|poland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06087549.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06087549*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*